title: ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities.
abstract: Positive allosteric modulators (PAMs) of metabotropic glutamate receptor subtype 5 (mGlu5) enhance N-methyl-d-aspartate receptor function and may represent a novel approach for the treatment of schizophrenia. ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone], a recently identified potent and selective mGlu5 PAM, increased (9-fold) the response to threshold concentration of glutamate (50 nM) in fluorometric Ca(2+) assays (EC(50) = 170 nM) in human embryonic kidney 293 cells expressing rat mGlu5. In the same system, ADX47273 dose-dependently shifted mGlu5 receptor glutamate response curve to the left (9-fold at 1 microM) and competed for binding of [(3)H]2-methyl-6-(phenylethynyl)pyridine (K(i) = 4.3 microM), but not [(3)H]quisqualate. In vivo, ADX47273 increased extracellular signal-regulated kinase and cAMP-responsive element-binding protein phosphorylation in hippocampus and prefrontal cortex, both of which are critical for glutamate-mediated signal transduction mechanisms. In models sensitive to antipsychotic drug treatment, ADX47273 reduced rat-conditioned avoidance responding [minimal effective dose (MED) = 30 mg/kg i.p.] and decreased mouse apomorphine-induced climbing (MED = 100 mg/kg i.p.), with little effect on stereotypy or catalepsy. Furthermore, ADX47273 blocked phencyclidine, apomorphine, and amphetamine-induced locomotor activities (MED = 100 mg/kg i.p.) in mice and decreased extracellular levels of dopamine in the nucleus accumbens, but not in the striatum, in rats. In cognition models, ADX47273 increased novel object recognition (MED = 1 mg/kg i.p.) and reduced impulsivity in the five-choice serial reaction time test (MED = 10 mg/kg i.p.) in rats. Taken together, these effects are consistent with the hypothesis that allosteric potentiation of mGlu5 may provide a novel approach for development of antipsychotic and procognitive agents.
authors.affiliation: Wyeth Neuroscience Discovery Research, Princeton, New Jersey, USA. liuf2@wyeth.com
authors.forename: Feng
authors.initials: F
authors.lastname: Liu
authors.forename: Steve
authors.initials: S
authors.lastname: Grauer
authors.forename: Cody
authors.initials: C
authors.lastname: Kelley
authors.forename: Rachel
authors.initials: R
authors.lastname: Navarra
authors.forename: Radka
authors.initials: R
authors.lastname: Graf
authors.forename: Guoming
authors.initials: G
authors.lastname: Zhang
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Atkinson
authors.forename: Michael
authors.initials: M
authors.lastname: Popiolek
authors.forename: Caitlin
authors.initials: C
authors.lastname: Wantuch
authors.forename: Xavier
authors.initials: X
authors.lastname: Khawaja
authors.forename: Deborah
authors.initials: D
authors.lastname: Smith
authors.forename: Michael
authors.initials: M
authors.lastname: Olsen
authors.forename: Evguenia
authors.initials: E
authors.lastname: Kouranova
authors.forename: Margaret
authors.initials: M
authors.lastname: Lai
authors.forename: Farhana
authors.initials: F
authors.lastname: Pruthi
authors.forename: Claudine
authors.initials: C
authors.lastname: Pulicicchio
authors.forename: Mark
authors.initials: M
authors.lastname: Day
authors.forename: Adam
authors.initials: A
authors.lastname: Gilbert
authors.forename: Mark H
authors.initials: MH
authors.lastname: Pausch
authors.forename: Nicholas J
authors.initials: NJ
authors.lastname: Brandon
authors.forename: Chad E
authors.initials: CE
authors.lastname: Beyer
authors.forename: Tom A
authors.initials: TA
authors.lastname: Comery
authors.forename: Sheree
authors.initials: S
authors.lastname: Logue
authors.forename: Sharon
authors.initials: S
authors.lastname: Rosenzweig-Lipson
authors.forename: Karen L
authors.initials: KL
authors.lastname: Marquis